CXCR4 and neoplasm: With regard to the second direction of incorporation of CXCR4 antagonist into ICIs therapeutic protocols, several preclinical works have indicated that CXCL12/CXCR4 interactions in the tumor microenvironment mediate immune evasion and resistance to ICIs.